PARVA-CAL 250 (calcium carbonate,calcium gluconate/ergocalciferol (vit D2))
CALCIUM · VITAMIN D DEFICIENCY ·+5
FREEDA VITAMINS
Drug class
Vitamin D
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis. Read more about Vitamin D
307 drugs in this class 101 manufacturers
Drugs in Vitamin D
VITAMIN D3 (calcium citrate,phosphate/vitamin D3/vit B6/folic ac/vit B12)
VITAMIN D · VITAMIN DEFICIENCY ·+3
MASON DISTRIB.
MULTIVITAMIN WITH FLUORIDE (pediatric multivitamins no.17 with sodium fluoride)
FLUORIDES · VITAMIN DEFICIENCY ·+1
SANCILIO & COMP
TRI-VITAMIN WITH FLUORIDE (pediatric multivit with A,C,D3 no.21/sodium fluoride)
FLUORIDES · VITAMIN DEFICIENCY ·+1
SANCILIO & COMP
CHOLECALCIFEROL (VITAMIN D3)
VITAMIN D · HYPOPARATHYROIDISM ·+6
RUGBY
CALCIUM 600 + VIT D (calcium carbonate/cholecalciferol (vitamin D3))
CALCIUM · VITAMIN D DEFICIENCY ·+5
PHARMAVITE
CALCIUM 500-VIT D3 (calcium carbonate/cholecalciferol (vitamin D3))
CALCIUM · VITAMIN D DEFICIENCY ·+5
PHARMAVITE
CALCIUM + D3 (calcium carbonate and citrate/cholecalciferol (vit D3))
CALCIUM · VITAMIN D DEFICIENCY ·+5
Walgreen Co
REPLESTA NX (cholecalciferol (vitamin D3))
VITAMIN D · HYPOPARATHYROIDISM ·+6
EVERIDIS HEALTH
Filter & compare in the drug finder →
Opens the drug finder with Vitamin D preselected. Add indication or manufacturer filters there.
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis.
Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling.
Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney disease.
-
fda.gov
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis
-
fda.gov
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling Clinically, these agents a...
-
cancer.gov
The vitamin D therapeutic drug class comprises fat-soluble secosteroid compounds and analogs, most notably ergocalciferol and cholecalciferol, that function as essential hormonal precursors in mineral homeostasis
-
nih.gov
Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney d...
-
nih.gov
Agents in this class undergo sequential hepatic and renal hydroxylation into biologically active forms that bind intracellular vitamin D receptors, enhancing intestinal absorption and renal reabsorption of calcium and phosphate while regulating bone remodeling
-
fda.gov
Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney disease
-
fda.gov
Clinically, these agents are primarily indicated for the prevention and treatment of nutritional rickets, osteomalacia, osteoporosis, hypocalcemia associated with hypoparathyroidism, and metabolic bone disease secondary to chronic kidney disease
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.